Stockscreener 앱 받기
12.79
0.43%
0.055
시간 외 거래:
12.80
0.01
+0.08%
전일 마감가:
$12.73
열려 있는:
$12.58
하루 거래량:
1.23M
Relative Volume:
0.49
시가총액:
$4.08B
수익:
$3.05B
순이익/손실:
$181.32M
주가수익비율:
34.23
EPS:
0.3737
순현금흐름:
$225.64M
1주 성능:
-0.23%
1개월 성능:
+7.93%
6개월 성능:
+22.63%
1년 성능:
+65.03%
1일 변동 폭
$12.55
$12.85
1주일 범위
$12.35
$13.03
52주 변동 폭
$7.02
$15.42
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
명칭
Amneal Pharmaceuticals Inc
전화
908-947-3120
주소
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
12.79 | 4.06B | 3.05B | 181.32M | 225.64M | 0.3737 |
TAK
Takeda Pharmaceutical Co Adr
|
16.30 | 51.84B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
113.83 | 49.05B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.30 | 42.09B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.38 | 36.82B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
571.07 | 24.94B | 3.18B | 1.33B | 1.04B | 27.90 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-17 | 개시 | UBS | Buy |
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-06-06 | 개시 | Goldman | Buy |
| 2025-02-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-09-06 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | 업그레이드 | Goldman | Sell → Buy |
| 2020-12-14 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-12-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-07-27 | 개시 | Goldman | Sell |
| 2020-05-12 | 업그레이드 | Guggenheim | Sell → Neutral |
| 2019-12-12 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-07 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | 개시 | Barclays | Equal Weight |
| 2019-05-21 | 업그레이드 | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2019-03-08 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | 다운그레이드 | SunTrust | Buy → Hold |
| 2018-08-13 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | 개시 | Morgan Stanley | Overweight |
| 2018-06-22 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
Amneal Pharmaceuticals Inc 주식(AMRX)의 최신 뉴스
Here's why Amneal Pharmaceuticals (AMRX) is a strong growth stock - MSN
Amneal Pharmaceuticals (AMRX) is a top-ranked momentum stock: Should you buy? - MSN
Is Amneal (AMRX) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
AMRX: 3 growth drivers behind Amneal's 2026 outlook - MSN
Wall Street Analysts See a 34.77% Upside in Amneal (AMRX): Can the Stock Really Move This High? - Yahoo Finance
Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now? - Yahoo! Finance Canada
Here's how AMRX is tapping GLP-1 demand through manufacturing - MSN
AMRX Should I Buy - Intellectia AI
Amneal to buy Kashiv in $750M deal; raises FY26 EPS outlook - MSN
AMRX growth drivers: Generics, biosimilars, and Crexont - MSN
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024 - Quantisnow
Amneal 2026-2027 Upside From Biosimilars Scale - Zacks Investment Research
AMRX Valuation: What 1.69x Sales Means for Investors - Yahoo Finance
AMRX Growth Drivers: Generics, Biosimilars, and Crexont - Yahoo Finance Australia
BlackRock (NYSE: AMRX) holds 24.1M shares, 7.6% stake reported - Stock Titan
Amneal Pharma to acquire Kashiv BioSciences to create fully integrated global biosimilar leader - MSN
Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock - Yahoo Finance
Amneal initiates nationwide settlement for opioid-related claims - MSN
Why Amneal Pharmaceuticals (AMRX) is a top growth stock for the long term - MSN
Amneal rated buy in new research coverage at UBS as growth pipeline expands - MSN
Assessing Amneal Pharmaceuticals (AMRX) Valuation After Strong Multi Year Returns And Recent Share Price Cooldown - Yahoo Finance
Amneal Kashiv Deal Shifts Biosimilar Growth And Valuation Story - Sahm
UBS initiates coverage of Amneal Pharmaceuticals (AMRX) with buy recommendation - MSN
Amneal anticipates deleveraging below 3x by 2028 as it outlines $4.3B-$4.5B 2030 revenue target following Kashiv deal - MSN
Amneal Acquires Kashiv BioSciences for $750 Million Upfront - HarianBasis.co
Amneal Pharmaceuticals to Buy Kashiv BioSciences, Touts Strong Preliminary Q1 Results and Biosimilar Push - MarketBeat
AMRX Price Today: Amneal Pharmaceuticals, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
2DT Stock Price and Chart — TRADEGATE:2DT - TradingView
Why Is Amneal Pharmaceuticals Stock Gaining Today? - Sahm
AMRX Announces Kashiv BioSciences Buyout, Solid Q1 Preliminary Results - The Globe and Mail
Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Amneal agrees to buy Kashiv BioSciences - The Pharma Letter
Amneal Pharmaceuticals Inc (AMRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.58%
2.43%
자본화:
|
볼륨(24시간):